LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Romidepsin for Injection, the newest addition to the company’s broad portfolio of injectable oncology medicines.
While formally announcing the withdrawal of the peripheral T-cell lymphoma (PTCL) indication for Bristol Myers Squibb’s Istodax (romidepsin) for injection (the company made a similar announcement last summer) on Friday, the agency also said it’s pulling Teva’s 505(b)(2) application, after the cancer drug failed its confirmatory trial.
Fresenius Kabi`s Generic Romidepsin Receives Approval in the US
Enforcement Report - Week of March 24, 2021
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has signed a new, exclusive patent license and research agreement with The Scripps Research Institute (TSRI), gaining access to groundbreaking, pre-clinical discoveries by Dr. Brunie Felding.